Zimhi Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027072 ADAMIS PHARMS CORP Emergency devices
May, 2039

(14 years from now)

US11571518 ADAMIS PHARMS CORP Emergency devices
Jun, 2041

(16 years from now)



Zimhi is a drug owned by Adamis Pharmaceuticals Corp. It is used for administering a therapeutic dose of an opioid antagonist in emergency situations. Zimhi uses Naloxone Hydrochloride as an active ingredient. Zimhi was launched by Adamis Pharms Corp in 2021. It is is available in solution form for intramuscular, subcutaneous use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 14, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a window configured to allow the user to view the opioid antagonist in the syring...

Dosage: SOLUTION

More Information on Dosage

ZIMHI family patents

Family Patents